Propanc Biopharma (PPCB) Cash from Financing Activities (2011 - 2025)
Propanc Biopharma (PPCB) posted quarterly Cash from Financing Activities of $965099.0 for Q4 2025, up 1660.62% year-over-year from $54816.0 in Q4 2024, and down 61.81% quarter-over-quarter from $2.5 million in Q3 2025.
Propanc Biopharma (PPCB) Cash from Financing Activities (2011 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Cash from Financing Activities for 15 consecutive years, with $965099.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 1660.62% year-over-year to $965099.0; the TTM figure through Dec 2025 stood at $3.7 million (up 531.17% YoY), while the FY2025 annual figure was $490756.0, down 47.9% from the prior year.
- Cash from Financing Activities slipped to $965099.0 in Q4 2025 per PPCB's latest filing, from $2.5 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $2.5 million in Q3 2025 and bottomed at $7756.0 in Q2 2025.
- Historically, Cash from Financing Activities has averaged $411451.3 across 5 years, with a median of $271714.5 in 2023.
- On a YoY basis, Cash from Financing Activities climbed as much as 1660.62% in 2025 and fell as far as 96.91% in 2025.
- Propanc Biopharma's Cash from Financing Activities stood at $354500.0 in 2021, then dropped by 29.48% to $250000.0 in 2022, then rose by 9.57% to $273929.0 in 2023, then plunged by 79.99% to $54816.0 in 2024, then soared by 1660.62% to $965099.0 in 2025.
- Business Quant data shows PPCB's Cash from Financing Activities at $965099.0 in Q4 2025, $2.5 million in Q3 2025, and $7756.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | -273.15 Mn |
| 10 | Propanc Biopharma | 577,167.14 | 577,167.14 | - | 965,099.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 965,099.00 |
| Dec 31, 2025 | 965,099.00 |
| Sep 30, 2025 | 2.53 Mn |
| Sep 30, 2025 | 2.53 Mn |
| Jun 30, 2025 | 7,756.00 |
| Jun 30, 2025 | 7,756.00 |
| Mar 31, 2025 | 212,485.00 |
| Mar 31, 2025 | 212,485.00 |
| Dec 31, 2024 | 54,816.00 |
| Dec 31, 2024 | 54,816.00 |
| Sep 30, 2024 | 215,699.00 |
| Sep 30, 2024 | 215,699.00 |
| Jun 30, 2024 | 250,974.00 |
| Jun 30, 2024 | 250,974.00 |
| Mar 31, 2024 | 66,644.00 |
| Mar 31, 2024 | 66,644.00 |
| Dec 31, 2023 | 273,929.00 |
| Dec 31, 2023 | 273,929.00 |
| Sep 30, 2023 | 350,347.00 |
| Sep 30, 2023 | 350,347.00 |